To characterize the prevalence of BRCA mutations and characteristics of BRCA carriers in China and to update the clinical recommendations for BRCA testing, we conducted a wide screen for BRCA mutations using next-generation sequencing (NGS). A total of 4,034 Chinese subjects were screened for germline BRCA1/2 mutations, including 2,991 breast cancer patients and 1,043 healthy individuals from the community enrolled as controls. We developed an NGS-based approach to perform BRCA1/ 2 screening. BRCA mutations were identified in 9.1% (232/2,560) of cases with at least one risk factor, in 3.5% (15/431) of sporadic patients and in 0.38% (4/1,043) of healthy controls. The mutation frequency ranged from 8.9 to 15.2% in cohorts with a single risk factor to 16.6-100% in groups with multiple risk factors. We identified 70 novel BRCA mutations. A high frequency of BRCA1 c.5470_5477del was detected, accounting for 13.9% (16/115) of the BRCA1 mutations detected in our study. Clinical characteristics such as family history, invasive carcinoma, negative human epidermal growth factor receptor 2 (HER2), high Ki67 index, lymph node status, and high tumour grade were closely related to BRCA mutations. BRCA2 carriers had poorer disease-free survival among HER2-or hormone receptor-positive patients (hazard ratio 5 1.892; 95% confidence interval: 1.132-3.161; p 5 0.013). This study shows that BRCA mutation carriers could be frequently identified among breast cancer patients with multiple risk factors. Importantly, we established an NGS-based pipeline for BRCA1/2 testing in clinical practice and strongly suggest that breast cancer patients of premier-and moderate-grade risks receive BRCA1/2 mutations testing in China.
Introduction
Breast cancer susceptibility is strongly associated with a patient's hereditary background, particularly the two major breast cancer predisposition genes, BRCA1 and BRCA2.
1,2
The cumulative risk of developing breast cancer by 70 years of age is approximately 37.9% for BRCA1 mutation carriers and 36.5% for BRCA2 mutation carriers, corresponding to a 10-fold increase compared with the general population in China. 3 The breast cancer risks reported for female BRCA1/2 mutation carriers reported in China are considerably lower than those in other countries. The hypothesis of allelic risk heterogeneity, in which different mutations confer different risks and penetrance in ethnicities is mutation specific, may explain this the phenomenon. This disparity has motivated increasing interest in a comprehensive understanding of the prevalence of BRCA1/2 in the Chinese population. It is estimated that 1,768 distinct BRCA1 variants and 1,994 distinct BRCA2 variants are listed in the Breast Cancer Information Core (BIC) (open access data, latest modification: November 2012), 4 including only 41 (2.1%) BRCA1 mutations and 34 (1.7%) BRCA2 mutations identified in the Chinese population. A meta study 5 in which of all Chinese cases with BRCA1 and/or BRCA2 mutations were assessed identified only 137 distinct BRCA1 variants and 80 distinct BRCA2 variants. The decision to perform BRCA mutation testing is mainly guided by a family history of breast cancer and/or ovarian cancer, which is indicative of a certain probability of the occurrence of inherited germline mutations. The presence of two primary cancers in one individual, such as bilateral breast cancers and breast cancers with ovarian cancer, male breast cancer, tripe-negative breast cancer (TNBC) and earlyage onset breast cancer, are also indicative of high BRCA mutation rates. The National Comprehensive Cancer Network (NCCN) has set criteria for further genetic risk evaluations, and all subtypes of breast cancers mentioned above are included. 6 However, no consensus regarding the identification of BRCA mutation carriers and clinical management options for BRCA carriers has been integrated in Chinese guidelines. Remarkable advances in next-generation sequencing (NGS) technology have provided read lengths as long as some entire genomes, reduced the cost of sequencing, and enabled the use of sequencing as a clinical tool for genetic testing. In this study, we aim to provide more information about the spectrum of BRCA1 and BRCA2 mutations in the Chinese population, to identify mutation rates in high-risk breast cancer, and to revise the clinical recommendations for genetic testing.
Materials and Methods

Cases and samples
Breast cancer patients with any one of the five following risk criteria were assigned to risk groups in the present study: (i) pathological diagnosis of TNBC, (ii) male breast cancer, (iii) primary bilateral breast cancers in one individual, regardless of synchrony or asynchrony, (iv) early-age onset breast cancer (less than or equal to 40 years of age at diagnosis), and (v) patients with a family history of breast and/or ovarian cancer (at least one first-and/or second-degree relative with breast cancer or ovarian cancer). All the cases were collected from three medical centres in China, which were Fudan University Shanghai Cancer Center, Shanghai; the Affiliated Union Hospital of Fujian Medical University, Fuzhou; and Shanghai First Maternity and Infant Hospital, Shanghai. Finally, a total of 2,560 patients were enrolled in the risk groups, and 431 breast cancer patients not meeting criteria were enrolled in the sporadic group. A total of 1,043 healthy people were further enrolled in the control group (basic information about the control group is provided in Table  S1 ). All samples were included in the study with approval from the independent ethical committee/institutional review board, and all participants signed informed consent forms.
BRCA1/2 testing
BRCA1/2 germline mutations were tested for all patients and controls. All coding regions and exon-intron boundaries of the BRCA1/2 genes were screened. The average intronic sequence length was 70 bp (ranging from 5 to 204 bp). The detailed procedures of NGS and interpretation of the mutations are described in the Supporting information and in the "Materials and Methods" section. Large genomic rearrangements (LGRs) in BRCA1/2 were not included in the present study. The sequencing results were compared with the BRCA1 (NM_007294.3) and BRCA2 (NM_000059.3) reference sequences for variant detection. All mutations considered disease-associated were validated via Sanger sequencing.
What's new?
Chinese women carrying BRCA mutations are at lower risk of breast cancer compared with female carriers in other countries, a phenomenon that may explained by associations between ethnic background and specific BRCA variants. Little is known, however, about BRCA1/2 mutation prevalence and related clinical characteristics among Chinese women. Here, overall BRCA1/2 mutation frequency was found to be 9.1% in Chinese breast cancer patients, compared with 0.38% in healthy Chinese controls, based on next-generation sequencing (NGS) analyses. BRCA mutations were closely associated with clinical characteristics, including family history and tumour grade. BRCA mutation carriers could be readily identified by NGS testing.
Statistical analysis
The v 2 test and Fisher's exact test were used to evaluate differences in BRCA1/2 mutation frequency across groups and the clinicopathological characteristics of BRCA mutation carriers. Survival outcomes were estimated using the KaplanMeier method, and differences were tested using the log-rank test. The multivariable Cox regression analysis was used to compare survival in BRCA-associated versus non-BRCA-associated breast cancer after adjustment for age, tumour stage, ER and PR status. All analyses were performed using SPSS software version 20.0 (IBM institute, Chicago, IL, USA). All p values were two-sided, and p < 0.05 was considered statistically significant.
Results
Description of the NGS dataset and BRCA mutation frequency Variants defined as pathogenic/likely pathogenic were selected for further analysis. BRCA mutation carriers were identified in 0.38% (4/1,043) of the community-based healthy population. When 33 people with a family history of breast cancer were excluded from analysis, the mutation rate was 0.40% (4/1,010) among the remainder of the healthy cohort. The BRCA mutation rate was 9.1% (232/2,560) in the risk cohort of clinic-based breast cancer patients and 3.5% (15/ 431) in the sporadic cohort of patients (Table 1) . Among the patients with risk factors, 92 BRCA1/2 mutation carriers were identified among 1,036 early-age onset breast cancer patients (8.9%); 98 carriers were found among 773 patients with family history (12.7%); 102 TNBC patients had BRCA1/2 mutations (10.1%); seven BRCA2 mutation carriers were found in 46 male patients (15.2%); and in 216 bilateral breast cancer patients, 27 BRCA1/2 mutation carriers were identified (12.5%). Analysis of the BRCA mutation frequency in the combined-risk groups revealed that the frequency was much higher when two risk factors were considered ( Table 2) . Family history of breast and/or ovarian cancer was the main factor leading to the high frequency of BRCA mutation carriers. When bilateral breast cancer and family history were combined, 32% of patients were identified as BRCA mutation carriers. Similarly, 100% of patients were identified as BRCA mutation carriers when male breast cancer and family history were combined. As denoted in bold in Table 2 , the seven groups with combined-risk factors had a BRCA mutation frequency of >16%.
Associations between patients' characteristics and BRCA mutation status Among the 1,009 patients diagnosed with TNBC, 69 patients (6.9%) had BRCA1 mutations, and 32 patients (3.2%) had BRCA2 mutations (Table 1) . BRCA1 mutation carriers were closely associated with the occurrence of TNBC (P < 0.001). We further distinguished 113 TNBC patients with a positive family history of breast and/or ovarian cancer among the 1,009 patients, and the BRCA1/2 mutation rate was significantly higher than in those with a negative family history (23.0 vs. 8.5%, p < 0.001). Among the 773 patients with relatives who were diagnosed with breast and/or ovarian cancer, 33 patients (4.3%) had BRCA1 mutations and 65 patients (8.4%) had BRCA2 mutations (Table 1) . Patients with a family history of breast cancer were more likely to test positive for BRCA2 (Table 1 , p < 0.001), and the likelihood was positively correlated with the number of affected relatives (Table  3 , p < 0.001). BRCA1-associated breast cancers occurred more frequently in patients who had relatives with ovarian cancer (p < 0.001). Patients with a second cancer (including thyroid, ovarian, lung, colon, parotid and cervical cancer) had a higher BRCA mutation rate (p 5 0.046). These findings suggest that a family and personal history of cancer strongly indicate BRCA mutation occurrence, and the probability of BRCA1 mutation occurrence increased with the number of family members affected with breast cancer. Among the 1,036 early-age onset breast cancer patients, 44 patients (4.2%) had BRCA1 mutations and 48 patients (4.7%) had BRCA2 mutations (Table 1 ). Patients diagnosed before the age of 40 years did not show a higher rate of BRCA mutation than older patients (Table 3 , p 5 0.368). We further compared the mean age in the whole cohort, and the BRCA1/2 mutation carriers in our study were significantly younger than non-carriers (carriers vs. non-carriers, 45.4 vs. 47.3 years, p 5 0.029). No male was detected positive for mutations in BRCA1, and seven patients (15.2%) had BRCA2 mutations among 46 male patients ( Table 1 ). The male patients had a significantly higher BRCA2 mutation rate (p 5 0.005). Among the 216 bilateral breast cancer patients (either synchronous or asynchronous), 12 patients (5.6%) tested BRCA1-positive and 15 patients (6.9%) tested BRCA2-positive (Table 1) . A higher frequency of BRCA mutation carriers was identified in bilateral breast cancer patients than in unilateral breast cancer patients (p 5 0.019). In the entire community-based population, the BRCA1 and BRCA2 mutation frequencies were 0.09 and 0.29%, respectively. Among the 2,560 breast cancer patients with selected risk factors, the BRCA1 and BRCA2 mutation frequencies were 4.1 and 5.0%, respectively. The patients with risk factors presented a higher rate of BRCA mutation than the remaining sporadic breast cancer patients (9.1 vs. 3.5%, p < 0.001).
When each receptor was examined alone, BRCA1 carriers were more likely to be ER-or PR-negative than BRCA1 non- Cancer Genetics and Epigenetics Table 3 . Association of patient/tumour characteristics with germline BRCA1 and BRCA2 mutation status carriers (Table 3 , p < 0.001 for both ER and PR), whereas BRCA2-mutated breast cancers were more likely to be ER-or PR-positive (p < 0.001 for both ER and PR), suggesting that BRCA2-associated breast cancer includes a relatively larger proportion of the luminal subtype. HER2 expression was much lower in both BRCA1-and BRCA2-mutated patients than in non-carriers (both P 5 0.001). The Ki67 index and tumour grades of BRCA1-mutated cancers were higher than those of BRCA-negative cancers (both p < 0.001). BRCA1-mutated patients also presented a higher stage at the time of diagnosis (p 5 0.024). BRCA2 mutation carriers showed more positive lymph nodes (p 5 0.013). These findings support the more aggressive behaviour of BRCA-associated breast cancers compared with BRCA-negative breast cancers.
BRCA1 mutations
Seventy-seven different BRCA1 mutations were detected ( Fig. 1 and Table S2 ). Twenty-six of these mutations were identified for the first time in this study, including three nonsense mutations c.5470_5477del (5589del8), 7, [12] [13] [14] and c.5521del (5640delA). 7, 15, 16 The most common BRCA1 mutation detected in our screen was c.5470_5477del, which was identified in one healthy subject and fifteen breast cancer patients, accounting for 13.9% (16/115) of all BRCA1 mutations in our study. The c.5470_5477del mutation was reported in two Asian cases in the BIC database and seems to be specific to Asian ethnicity. We considered the BRCA1 mutations c.981_982del (1100delAT in original nomenclature) and c.5470_5477del (5589del8) to indicate a founder effect in the Chinese population in our previous study, 7 and we identified more affected carriers in the present study. The BRCA1 c.5521del mutation, which also appears to be specific to the Chinese population, was reported once in the BIC database, with no other records in other ethnicities. Interestingly, we found that one patient (code 30**54) exhibited BRCA1 mutations at two different, but proximal sites, c.2143_2147del and c.2155A>T, which both truncated the BRCA1 protein. One patient (code 30**17) who carried the BRCA1 mutation (c.4573C>T) also exhibited a frameshift deletion (c.2059_2063del) in BRCA2. Mutations identified clearly as pathogenic or likely pathogenic were enrolled in our analysis.
P1, non-carriers versus gBRCA1 carriers;
P2, non-carriers versus gBRCA2 carriers;
P3, non-carriers versus gBRCA1/2 carriers. Bold values denote two-sided
Abbreviations: gBRCA, germline breast cancer susceptibility gene; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
1 gBRCA1/2 carriers included gBRCA1 carriers, gBRCA2 carriers, and one carrier with both genes mutated.
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BRCA2 mutations
Ninety-eight different BRCA2 mutations were detected ( Fig.  1) , of which 96 were detected in 135 patients (Table S3) , while three were found in healthy controls (the BRCA2 c.2442del was found in both the patient and control groups). c.239_243del, c.1472del, c.1689del, c.1759_1763del, c.1847_  1848del, c.1913del, c.2012del, c.2017_2023del, c.2053del,  c.2176del, c.3263del, c.4467_4471del, c.4657_4658del, c.4744_  4747del, c.5795_5799del, c.5938del, c.6547del, c.7058del,  c.7498del, c.8172del, c.8941_8942del, and c.9290del) . Several BRCA2 mutations previously reported in the Chinese population were also identified, including c.262_263del, 9, 16 The most common BRCA2 mutations detected in our patient cohort were c.470_474del and c.3109C>T, which were both identified in five individuals. The BRCA2 c.470_474del mutation has only been detected in the Chinese population, particularly in individuals from the east of China. The BRCA2 c.3109C>T mutation had been reported in the BIC database from various countries, with half of the reports coming from China (9/18). The two identified BRCA2 mutations appear to be recurrent mutations in the Chinese population, but further confirmation in a larger cohort is needed. BRCA2 c.7409dupT carriers have been identified in two regions of China, 20, 21 and this mutation was detected in four breast cancer patients in our study. The BRCA2 c.6405_6409del mutation was recorded in the BIC database in diverse races, though the present study provided the first report of this mutation in the Chinese population.
One patient (code 33**53) exhibited two frameshift mutations (c.4467_4471del and c.4473_4474insTTTT) and one nonsense mutation (c.4474A>T).
Survival estimates
Follow-up data were available for 2,601 invasive breast cancer patients in our cohort. The median follow-up was 30 months (interquartile range: 20-45 months). A total of 283 patients experienced local recurrence and distant metastasis or died due to breast cancer.
There were no significant differences in disease-free survival (DFS) between the BRCA carriers and non-carriers We further divided the patients into specific subgroups to determine if the BRCA mutation status impacted DFS. Among the non-TNBC patients, BRCA2 mutation carriers had poorer DFS than BRCA2 mutation non-carriers (HR 5 1.892, 95% CI: 1.132-3.161, p 5 0.013; Fig. 1f) ; however, no significant relationship was observed between BRCA carriers and BRCA non-carriers (HR 5 1.520, 95% CI: 0.945-2.443, p 5 0.081; Fig. 2d ) or between BRCA1 carriers and BRCA1 non-carriers (HR 5 0.720, 95% CI: 0.230-2.255, p 5 0.570; Fig. 2e ). The survival results for the rest of the subgroups are presented in the Supporting information and in the "Materials and Methods" section.
Recommendations for BRCA screening in breast cancer patients
Based on the present large cohort study, we are of the opinion that Chinese clinicians should give breast cancer patients four grades of recommendations for BRCA mutation testing (Table 4) according to five risk factors (described in the "Materials and Methods" section): (i) premier-grade recommendation: bilateral breast cancers with family history of breast/ovarian cancer; male breast cancers with family history of breast/ovarian cancer; breast cancers with family history of at least three affected relatives diagnosed with breast/ovarian cancer; (ii) moderate-grade recommendation: breast cancers with any two of the five risk factors; breast cancers with family history of at least two affected relatives diagnosed with breast/ovarian cancer; (iii) low-grade recommendation: breast cancers with any one of the five risk factors; and (iv) inferior-grade recommendation: sporadic breast cancers without any one of the five risk factors.
Discussion
The present study is the first to perform BRCA mutation screening in a large number of breast cancer patients and healthy controls using NGS in China. This is also the first study of BRCA1/2 mutations screening in unselected Chinese healthy subjects and the largest BRCA1/2 mutations analysis in Chinese breast cancer patients with risk factors to date. All coding regions and exon-intron boundaries of the BRCA1/2 genes were tested for all patients and controls. Clinic-based screening indicated that the BRCA1/2 mutation frequency was approximately 9.1% in breast cancer patients with at least one risk factor from the five categories. Communitybased screening revealed that the BRCA1/2 mutation frequency was approximately 0.38% in unselected healthy people, much lower than the rate in healthy Ashkenazi Jewish women while approximately equal to that in American women. 22, 23 The prevalence rates of BRCA1 and BRCA2 mutations in our entire breast cancer cohort were 3.7 and 4.5% separately, comparable to data across other Asian countries. 19 BRCA2 mutations were more likely to be observed in Chinese patients, than in Caucasian, particularly Latin American, patients. 24 At the same time, there existed distinct population-dependent differences from country to country.
The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) presented a comprehensive BRCA screening and revealed a higher mutation frequency in BRCA1 than that in BRCA2. 25 In contrast, studies in the United Kingdom demonstrated a similar or inferior prevalence of BRCA1 mutations compared with BRCA2 mutations. 26, 27 The frequencies of BRCA1/2 mutation in early-age onset breast cancers, familial breast cancers, and TNBC groups were similar to those observed in other studies in China ranging from 2.6 to 9.5% for BRCA1 and 2.3 to 9.4% for BRCA2. 7, 9, [14] [15] [16] 28 Our results suggested that bilateral breast cancers had a high BRCA1/2 mutation frequency of 12.5%, and male breast cancers had an even higher mutation frequency of 15.2%. In accordance with the British, Spanish and Belgian studies, [29] [30] [31] only BRCA2 and not BRCA1 mutation carriers were identified in male breast cancers. However, the recent study from GC-HBOC comprised 671 male breast cancer patients and they had a BRCA1 mutation frequency of 9.2%. 25 Among the male breast cancer families where additional ovarian cancer cases presented, a comparable prevalence of mutations was found between BRCA1 and BRCA2, suggesting a different hereditary background in male patients with ovarian cancer family history. Notably, they also found an extremely high BRCA2 mutation frequency of 65.2% in the families characterized by more than two male breast cancers and one female breast cancer. Our study strengthens evidence that male breast cancers are tightly associated with hereditary background, especially BRCA2 mutations. The combined-risk groups had an elevated BRCA mutation frequency in the present study ranging from 16.6 to 100%. This result is consistent with previous studies in China. 7, 16, 28 In the Caucasian and other populations, a high prevalence of BRCA mutations was frequently found in the combined-risk breast cancer patients. It was reported that approximately 31% of the bilateral breast cancer patients diagnosed at an early age (younger than 50 years) had BRCA mutation in the GC-HBOC study. 25 In our cohort, we analysed bilateral breast cancer patients younger than 40 years old and the mutation rate was 20%, but we did not acquire a higher rate if we further included the patients younger than 50 years old. In the cohort of the bilateral breast cancer patients with at least one breast cancer relative, BRCA mutation rate (approximately 27%) in the GC-HBOC was comparable in our study. Intriguingly, the British study 32 revealed the result that approximately 41% of the bilateral breast cancer (the first diagnosed before 45) patients had BRCA mutations, and the rate increased to 61% if the patients had a family history of ovarian cancer. The GC-HBOC study 25 divided the patients into the younger and the older cohorts by the age of 50 years. In the younger cohort, approximately 18% of the breast cancer families (at least two breasts cancer and no ovarian cancer) were detected BRCA-positive, which was similar to our result. Their study also indicated that approximately 32% of the breast and ovarian cancer families (at least one young breast cancer and one ovarian cancer) inherited BRCA mutations, whereas we did not observe many patients of these kinds. International organizations have officially incorporated TNBC as one of BRCA testing criteria in their guidelines. 6, [33] [34] [35] In recent publications, BRCA screening was conducted in the TNBC patients regardless of family history. Wong-Brown et al. 36 studied 439 Australian and 335 Polish TNBC patients, and among the patients younger than 40 years old, 15% of the Australian and 36% of the Polish patients were identified as BRCA carriers, respectively. Greenup et al. 37 undertook BRCA mutation testing among 469 TNBC patients from diverse ethnicities and observed a high mutation prevalence of 44% among the patients younger than 40 years old. Generally, compared with our findings, BRCA mutations were more frequently detected in the combined-risk cohorts in the western studies.
We developed an NGS-based pipeline for variant analysis of the BRCA1 and BRCA2 genes, which was applied for further clinical diagnosis in Chinese clinical centres. Based on a large number of patients and a high-throughput platform, we reported the clinical and pathological characteristics of the tumours of cohorts of patients with BRCA-negative and BRCA-positive breast cancers. We clarified that the BRCA1 and the BRCA2 mutated breast cancers had opposite relationships with ER and PR status, that is, BRCA1-positve tumours had significantly lower expression, whereas BRCA2-positive tumours had higher expression. Some researchers failed to observe an association between BRCA status and HER2 status in smaller sample size. 16, 38 In our study, both BRCA1-and BRCA2-positive breast cancers were more likely to be HER2-negative. This conclusion was also confirmed by another large study in China. 28 Significantly, more BRCA1-positive breast cancers were TNBC compared with BRCA-negative and BRCA2-positive breast cancers. In addition, BRCA1-positive breast cancers were poorly differentiated along with patterns of pathogenic characteristics such as invasive ductal carcinoma, high expression of Ki67, high tumour grade and stage. By contrast, BRCA2-positive breast cancers clustered in the luminal phenotype, with less malignancy and relatively moderate characteristics. However, BRCA2-positive breast cancers tended to have more positive lymph nodes, whereas BRCA1-positive breast cancers tended to have less, according to our results. Several previous studies examining the relationship between BRCA2 mutation status and breast cancer pathology have found similar results. In the investigation by Zhang et al., 28 43.6% of the BRCA2 carriers had positive lymph nodes, compared with 30.1% of the BRCA1 carriers (p 5 0.041). Similarly, a multicentre study 39 observed a significant difference in nodal metastasis between BRCA2 carriers and BRCA1 carriers (10.7 vs. 7.0%, p 5 0.033). These lines of evidences indicate BRCA1-positive and BRCA2-positive breast cancers are two diverse subgroups of breast malignancy. Furthermore, we found that BRCA2-positive breast cancer seemed to have a stronger connection with breast cancer hereditary background, whereas BRCA1-positive breast cancer was tightly related to a family history of ovarian cancer. These findings indicate that clinicians should consider pathology results and family history together when predicting whether a breast cancer patient is at risk of having a BRCA1/ 2 mutation. Little clinicopathological data could be found on breast cancer patients who have inherited both BRCA1 and BRCA2 mutations, but we detected one such carrier in our TNBC group. International research suggests that the prevalence of such dual inheritance is 0.3% (93/32,295). 40 The researchers observed that dual BRCA carriers resembled BRCA1 carriers in clinical phenotype and had characteristics of ER or PR expressions intermediate between BRCA1 carriers and BRCA2 carriers.
The median age of Chinese BRCA carriers diagnosed with breast cancer is 44.5 years. 3 We previously considered stricter criteria to determine the early-age onset group, and we set the cutoff line at 40 years. To our disappointment, the lack of significance of age in younger patients indicated that an age of 40 years is not an appropriate cutoff value in Chinese breast cancer patients. However, the age at diagnosis differs between carriers and non-carriers. The BRCA1/2 mutation carriers in our study were significantly younger than noncarriers (mean age, carriers vs. non-carriers, 45.4 vs. 47.3 years, p 5 0.029). When we re-calculated and interpreted our data (results not showed), we found that an age of 45 years seemed to be a better cutoff value to distinguish BRCA carriers in younger patients. However, this conclusion might be less convincing because the young patients in our study mainly comprised patients younger than 40 years of age. The main aim of our study was to try to identify BRCA mutation rates in specific groups of Chinese breast cancer patients and the likelihood that different groups carry a BRCA mutation. Based on these results, we would like to retain the cutoff value in our current recommendation, but the age of 45 years was significant in younger patients, and this cutoff will be applied in our subsequent studies.
We failed to demonstrate distinct DFS between BRCAassociated and non-BRCA-associated breast cancer patients in both univariable and multivariable analyses. BRCA-associated cancers had unique histopathological features compared to sporadic breast cancers. 38, 39 They were usually high-grade, poorly differentiated, and had a higher frequency of somatic abnormalities. The biological background of BRCA and different pathological aspects of tumours support the hypothesis that patients carrying a BRCA1 and/or BRCA2 mutation might have a worse prognosis compared to non-carriers. However, BRCA-associated tumours are more susceptible to DNA-damage agents, which is advantageous for chemotherapy and treatments targeting DNA-repair pathways. 41 A retrospective study 9 demonstrated BRCA carriers a had better response to neoadjuvant anthracycline-based regimens. However, recurrence-free survival was similar between BRCA carriers and non-carriers among the 947 patients in that study. Thus, although BRCA mutation carriers responded better to systemic treatment, superior advancement in long-term survival was not observed. Similarly, two systematic reviews with meta-analysis 42, 43 concluded that current evidence did not support better or worse breast cancer survival of BRCA mutation carriers. In addition to the failure of BRCA mutation status as a prognostic factor in DFS, the study subjects were not further selected for surgery procedure, radiotherapy, and endocrine treatment, which might have influenced the survival rates. A large international prospective study 44 concluded that risk of distant recurrence was higher for BRCA2 mutation carriers compared with sporadic patients in univariable analysis, but the conclusion did not persist in multivariable analysis (adjusted for age, tumour stage and other ascertained factors). As a limitation, the median follow-up and the observed events in our study were both low. Previous international studies of large cohorts had long-term investigation of the clinical outcomes among BRCA-associated breast cancer and the median follow-up ranged from 72 to 120 months. [44] [45] [46] [47] [48] However, we only identified 283 events in total with a median follow-up of 30 months, and would come to a less evidential conclusion. Therefore, caution is required when interpreting our results. We will continue our study and keep track of survival events in the long-term follow-up.
Genetic testing and hereditary risk counselling for breast cancer have been established for years in foreign countries, and genetic testing criteria may differ among countries based on mutation prevalence. In Australia, genetic counselling and testing are offered to those with positive family history indicative of an approximately >10% chance of having a BRCA mutation, whereas less stringent criteria are applied in America. 41 Internationally accepted clinical criteria for referral can be obtained from The NCCN guidelines on genetic/ familial high-risk assessment, 6 and The National Institute for Health and Clinical Excellence (NICE) guidelines. 49 However, no official and systematic recommendations for hereditary risk consulting have been published in China. Olaparib 50 and cisplatin 51 are favourable therapeutic alternatives for novel treatment strategies in BRCA-deficient breast cancer patients. The application of BRCA mutation analysis has been extended to clinical treatment, in addition to pre-clinical treatment and prevention. However, the cost of DNA sequencing is still too high for most families. Chinese clinicians should carefully recommend highly susceptible patients for BRCA mutation testing. Based on the evidence obtained, BRCA-associated breast cancers show a pattern with more invasive and aggressive characteristics, and local and systematic treatment should be considered more seriously for BRCA-positive patients than BRCA-negative patients.
A limitation of our study is that LGRs were not included in the present screening program because multiplex ligationdependent probe amplification (MLPA) was not performed. A cross-national study demonstrated that LGRs comprise a significant fraction, between 6 and 10%, of all clinically significant BRCA mutations in diverse ethnicities. 52 In addition, that study revealed that the general prevalence of LGRs in breast cancer patients with a risk factor was 2.2% (551/ 25,535). Kwong et al. 53 reported a study in Chinese familial breast cancer patients, performing both full genes sequencing and MLPA. They identified 120 BRCA mutations, and LGRs accounted for 6.7% (8 of 120) of all BRCA mutations. Based on this evidence, the BRCA mutation frequency in our analysis could be underestimated by at least 6%, because we did not take LGRs into account. MLPA should be used to detect
LGRs in combination with NGS in further clinical use in BRCA1/2 mutation testing to avoid false-negative results.
In summary, our results revealed a comprehensive spectrum of BRCA1/2 mutations in Chinese population. Breast cancers with mutated BRCA1/2 genes differed from sporadic breast cancers in various aspects of clinical and pathological characteristics. Breast cancer patients at premier-and moderate-grade risks should be strongly recommended for BRCA1/2 mutation testing via NGS process or other methods in China. The identification of a BRCA1/2 mutation might help tailor treatment.
